News Releases

May 28, 2015
OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab and Tarextumab During Conference Call on Tuesday, June 2, 2015

REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, will host a conference call and webcast for investors on Tuesday, June 2, 2015 at 7:00 a.m. EDT to discuss data being presented at the 2015 ASCO Annual Meeting, being held May 29-June 2, 2015 in Chicago, IL.

To participate by telephone, please dial 855-420-0692 (Domestic) or 484-756-4194 (International). The conference ID number is 57579568. A live and archived audio webcast can be accessed through the Investors section of the Company's website at The web broadcast of the conference call will be available for replay through July 2, 2015.

OncoMed will have a total of three presentations on Monday, June 1, 2015 at the ASCO Annual Meeting covering Phase 1b clinical trial results for tarextumab (anti-Notch2/3, OMP-59R5) in small cell lung cancer (Abstract#7508), demcizumab (anti-DLL4, OMP-18M21) in pancreatic cancer (Abstract #4118) and demcizumab in non-small cell lung cancer (Abstract #8045). Copies of the posters will be available on the OncoMed website following their presentation.

Abstract #7508: Final results of phase 1b of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Lead author: Dr. M. Catherine Pietanza, MD, of Memorial Sloan-Kettering Cancer Center
Poster Discussion Session 1:15 pm - 2:30 pm CDT: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Discussion Session 1:15 pm – 2:30 pm CDT

Abstract #4118: A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.
Lead author: Manuel Hidalgo, MD, PhD, Director of the Centro Integral Oncológico Clara Campal (CIOCC), START Madrid
Poster Session 8:00 am - 11:30am CDT: Gastrointestinal (Noncolorectal) Cancer

Abstract #8045: A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients with 1st line non-squamous NSCLC.
Lead author: Dusan Kotasek MBBS, FRACP, Adelaide Cancer Centre
Poster Session 8:00 am - 11:30am CDT: Lung Cancer—Non-Small Cell Metastatic

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cell (CSC) and immuno-oncology pathways. OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website:

Media & Investors Investors
OncoMed Pharmaceuticals  Shari Annes
Michelle Corral Annes Associates
Senior Director, Investor Relations
and Corporate Communications (650) 888-0902  
(650) 995-8373  




OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site for our Pipeline, Partnering Opportunities and Investors information.